• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Predictive models for adverse clinical outcomes in Chinese patients with atrial fibrillation undergoing percutaneous coronary intervention with stenting
CONCLUSION: Chinese patients with AF and coronary stenting had high mortality and incidence of MACCE. We compiled separate predictive models for all-cause death, IS/STE, MACCE, and major bleeding.PMID:34353224 | DOI:10.1080/00015385.2021.1950367
Source: Acta Cardiologica - August 6, 2021 Category: Cardiology Authors: Jian-Yong Zheng Yi Cao Dong-Tao Li Yi-Gang Qiu Li Zhao Zheng-Ming Xu Yi-Xiong Huang Zhi-Bo Hong Tian-Chang Li Yi-Da Tang Cheng-Jun Guo Zhi-Min Ma Yong-Quan Wu Yu Chen Source Type: research

Indobufen or Aspirin on Top of Clopidogrel after Coronary Drug-eluting Stent Implantation (OPTION): a Randomized, Open-label, Endpoint-blinded, Non-inferiority Trial
Conclusions: In Chinese patients with negative cardiac troponin undergoing DES implantation, indobufen plus clopidogrel DAPT compared with aspirin plus clopidogrel DAPT significantly reduced the risk of 1-year net clinical outcomes, which was mainly driven by a reduction in bleeding events without an increase in ischemic events.PMID:36335890 | DOI:10.1161/CIRCULATIONAHA.122.062762
Source: Circulation - November 6, 2022 Category: Cardiology Authors: Hongyi Wu Lili Xu Xin Zhao Huanyi Zhang Kang Cheng Xiaoyan Wang Manhua Chen Guangping Li Jiangnan Huang Jun Lan Guanghe Wei Chi Zhang Yinman Wang Juying Qian Junbo Ge Source Type: research

Ability to Suppress TGF- β-Activated Myofibroblast Differentiation Distinguishes the Anti-pulmonary Fibrosis Efficacy of Two Danshen-Containing Chinese Herbal Medicine Prescriptions
Conclusion: This study suggests that a clinically efficacious cardiovascular Chinese herbal medicine (DLP) can be successfully repurposed to treat a lung disease in pulmonary fibrosis guided by TCM theory. Our comparative study between DLP and DHP demonstrated a critical requirement of suppressing both pro-inflammatory and pro-fibrotic pathways for the treatment of pulmonary fibrosis, supporting that a multi-component prescription capable of “removing both phlegm and blood stasis” will better achieve co-protection of heart and lung in PHD. Introduction Idiopathic pulmonary fibrosis (IPF) is a chronic ...
Source: Frontiers in Pharmacology - April 23, 2019 Category: Drugs & Pharmacology Source Type: research

Dual Antiplatelet Therapy Duration in Medically Managed Acute Coronary Syndrome Patients: Sub-Analysis of the OPT-CAD Study
ConclusionMMACS patients with insufficient DAPT management experienced relatively more ischemic events. DAPT for at least 1  year may be beneficial to this special population without significantly increasing the bleeding risks.Trial registrationClinicalTrials.gov identifier, NCT01735305.
Source: Advances in Therapy - May 15, 2020 Category: Drugs & Pharmacology Source Type: research

Safety and efficacy of low-dose ticagrelor in Chinese patients with acute coronary syndrome undergoing percutaneous coronary intervention
Platelets. 2021 Apr 4:1-8. doi: 10.1080/09537104.2021.1909717. Online ahead of print.ABSTRACTIt remains unclear whether low-dose ticagrelor offers better safety and similar efficacy for Asian patients with acute coronary syndromes (ACS). We aimed to compare the safety and effectiveness of low-dose ticagrelor vs standard-dose ticagrelor in Chinese patients with ACS undergoing percutaneous coronary intervention (PCI). In this observational cohort study, a total of 2110 ACS patients who were event-free at 3 months after the index PCI were divided into standard-dose ticagrelor (90 mg twice daily) (n = 1830) or low-dose ticagre...
Source: Platelets - April 5, 2021 Category: Hematology Authors: Yue Wang Beibei Liu Leilei Chen Yue Wang Zhiqiang Wang Xiaojiang Zhang Min Suo Gary S Mintz Xiaofan Wu Source Type: research

Analysis of individualized antiplatelet therapy for patients of acute coronary syndrome after percutaneous coronary intervention under the guidance of platelet function: A one-center retrospective cohort study
There is controversy in clinical application of antiplatelet drugs by monitoring platelet function. Therefore, we explored whether early and dynamic medication could bring better clinical outcomes for patients under the guidance of platelet function tests (PFT). In this retrospective cohort study, we analyzed the prognostic events of 1550 patients with acute coronary syndrome (ACS) at Tianjin People's Hospital in China. They received dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) from January 2017 to December 2018. The primary endpoint was based on the Bleeding Academic Research Consorti...
Source: Medicine - April 23, 2021 Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research

Pages: 1  2